The abstract is read at the publisher; the summary is JClub's.
YAP1 transcriptionally activates PLCβ1, and PLCβ1 suppresses NF-κB–dependent MHC-I antigen presentation, linking this axis to reduced anti–PD-1 responsiveness in gastrointestinal cancer patients.
- Why it matters: Immune checkpoint blockade often fails in gastrointestinal malignancies because tumors develop immune-evasive microenvironments that blunt antigen presentation and immunotherapy effectiveness.
- What they did: The study mapped a YAP1→PLCβ1 pathway, showing PLCβ1 interacts with ERC1 to promote its ubiquitin-proteasomal degradation, reducing NF-κB-driven MHC-I transcription; YAP inhibition restored MHC-I expression.
- The result: PLCβ1 expression was associated with reduced immunotherapy responsiveness in patients, and combining a YAP inhibitor with anti-PD-1 produced synergistic antitumor effects in syngeneic mice and patient-derived xenografts.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.